PRPH and Guillain-Barre syndrome: Peripherin and periaxin, biomarkers of peripheral nerve axonal damage and acute demyelination, respectively, have recently been validated in the inflammatory neuropathies Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).